CT Cardiomegaly vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CT Cardiomegaly

by Innolitics

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

Tool A assists in detecting cardiomegaly by measuring cardiothoracic ratios from CT images, providing quantitative data for structural heart assessment. In contrast, Tool B analyzes 12-lead ECGs to predict the risk of new-onset atrial fibrillation in older patients, focusing on electrical rhythm disorders. While both are FDA-cleared cardiology AI tools, they utilize different data modalities and address distinct cardiac conditions, making them suitable for different clinical use cases.

Choose CT Cardiomegaly if…

Choose CT Cardiomegaly if your facility requires an automated, quantitative solution for rapidly assessing cardiomegaly from existing CT chest images. This command-line software is ideal for environments needing precise linear and area-based cardiothoracic ratio measurements for diagnostic assistance or large-scale data analysis. It integrates well into workflows utilizing Docker containers for efficient processing and reporting.

View CT Cardiomegaly →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your clinical practice aims to proactively identify elderly patients at elevated risk of developing new-onset atrial fibrillation within the next year. This AI-based algorithm integrates with existing 12-lead ECG systems to support earlier intervention and follow-up for patients aged 65 or older, without pre-existing AF or certain cardiac devices. Its CMS reimbursement availability also makes it a financially viable option for risk stratification.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CT Cardiomegaly	Tempus ECG-AF
Pricing	Fixed-fee	Contact vendor
Deployment	Docker Container (Ubuntu 20.04), command-line software	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tempus ECG-AF

Tempus ECG-AF is designed for seamless integration into existing healthcare facility systems and EHRs via APIs, providing results within familiar clinical workflows without a dedicated user interface. In contrast, Innolitics' CT Cardiomegaly is a command-line software, which is inherently less user-friendly for typical clinical users and requires more technical expertise for operation and integration.

Clinical Value

Tempus ECG-AF

Tempus ECG-AF offers a predictive capability to identify patients at increased risk of developing atrial fibrillation within 12 months, enabling proactive intervention and potentially improving patient outcomes for a serious condition. While CT Cardiomegaly provides valuable quantitative diagnostic assistance for cardiomegaly detection, the predictive nature of Tempus ECG-AF for a future event represents a higher clinical impact in terms of preventative care.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF clearly outlines CMS reimbursement availability with specific CPT codes (0764T and 0765T) and a Medicare rate of $128.90, effective January 1, 2025, providing transparency and a clear financial pathway for adoption. Innolitics' CT Cardiomegaly only states 'contact for pricing,' offering no public information on its cost or potential reimbursement.

Enterprise Readiness

Tempus ECG-AF

Tempus ECG-AF demonstrates strong enterprise readiness through its explicit compatibility with major ECG vendors (GE Medical Systems and Philips Medical Systems) and its design for integration into existing healthcare facility systems via APIs and EHRs. While CT Cardiomegaly is deployed via Docker, Tempus ECG-AF's specific integration capabilities suggest a more seamless fit into complex clinical environments.

Innovation

Tempus ECG-AF

Tempus ECG-AF demonstrates greater innovation by utilizing AI for predictive analytics, identifying patients at risk of developing new-onset atrial fibrillation within 12 months from a standard ECG. This proactive risk stratification for a future medical event is a more advanced application of AI compared to CT Cardiomegaly's automation of a standard diagnostic measurement.

Support & Docs

Tempus ECG-AF

Tempus ECG-AF explicitly provides dedicated contact information for its Cardiology Support team, including an email address ([email protected]) and a phone number (800.739.4137), indicating clear channels for technical assistance and inquiries. Innolitics' CT Cardiomegaly does not provide specific product support contact details in the available information, only general contact for the company.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CT Cardiomegaly	Tempus ECG-AF
Name	CT Cardiomegaly	Tempus ECG-AF
Company	Innolitics	Tempus AI, Inc.
Primary Function	Automatically measures cardiothoracic ratio from CT chest images, assisting physicians in cardiomegaly detection with quantitative data.	Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Input Data Type	CT chest images	12-lead ECG recordings
Target Condition/Outcome	Cardiomegaly detection	Identification of patients at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months
Target Patient Population	Not specified	Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery

Videos

Demos, reviews, and walkthroughs featuring CT Cardiomegaly and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical purpose of each tool?

Innolitics' CT Cardiomegaly assists physicians in detecting cardiomegaly by automatically measuring the cardiothoracic ratio from CT chest images. Tempus ECG-AF analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.

What type of patient data is required for each tool?

CT Cardiomegaly requires CT chest images as input. Tempus ECG-AF analyzes 12-lead ECG recordings.

For which patient populations are these tools intended?

CT Cardiomegaly is intended for use with adults and transitional adolescents (18 to 21 years old but treated as an adult) who have CT images containing the heart. Tempus ECG-AF is specifically for patients aged 65 or older who do not have pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

What kind of output do these tools provide, and how should it be interpreted?

CT Cardiomegaly provides quantitative linear and area-based cardiothoracic ratios in PDF and JSON reports, assisting with cardiomegaly detection but not providing a diagnosis. Tempus ECG-AF identifies patients at increased risk of new onset AF within 12 months, with results that should be interpreted in conjunction with other diagnostic information, clinical history, and symptoms, and not as the sole basis for diagnosis or treatment of AF.

Is there any information regarding reimbursement for these tools?

For Tempus ECG-AF, CMS reimbursement is available with CPT codes 0764T and 0765T assigned to APC 5734, with a Medicare rate of $128.90, effective January 1, 2025. No specific reimbursement information is provided for Innolitics' CT Cardiomegaly in the given facts.

How were these tools developed or validated?

Innolitics' CT Cardiomegaly uses non-adaptive machine learning with the MONAI framework and was validated against manual measurements by board-certified radiologists. Tempus ECG-AF was trained on over 1.5 million ECGs from more than 500,000 patients and is compatible with FDA-authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.